Prevalence of DLL3, CTLA-4 and MSTN Expression in Patients with Small Cell Lung Cancer

INTRODUCTION: Immune-based and antibody-drug conjugate therapies have shown promise in the treatment of patients with small cell lung cancer (SCLC). However, better predictive biomarkers are needed for selection of the appropriate SCLC patients for these advanced therapies and also for evaluation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Regzedmaa, Orgilmaa, Li, Ying, Li, Yongwen, Zhang, Hongbing, Wang, Jin, Gong, Hao, Yuan, Yin, Li, Weiting, Liu, Hongyu, Chen, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877464/
https://www.ncbi.nlm.nih.gov/pubmed/31819500
http://dx.doi.org/10.2147/OTT.S216362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877464/
https://www.ncbi.nlm.nih.gov/pubmed/31819500
http://dx.doi.org/10.2147/OTT.S216362

Ejemplares similares